Formulation and evaluation of lovastatin oral disintegration thin films
Department of Pharmaceutics, CMR College of Pharmacy, Kandlakoya (V), Medchal Road, Hyderabad, India.
Research Article
GSC Biological and Pharmaceutical Sciences, 2018, 03(02), 035–042.
Article DOI: 10.30574/gscbps.2018.3.2.0061
Publication history:
Received on 12 October 2017; revised on 02 May 2018; accepted on 05 May 2018
Abstract:
Lovastatin is a statin drug used to prevent and treat coronary heart disease and to treat high cholesterol. In the present study, oral disintegrating thin films (ODTs) of lovastatin were designed with a view to enhance patient compliance by solvent casting method. In the solvent casting method, Croscarmellose sodium (CCS) (2, 4 and 6 % w/w), Crospovidone (10 and 15% w/w) as superdisintegrants were used in different concentrations with Gelatin, Poly vinyl alcohol (PVA) as a film forming base for the formulation of oral disintegrating thin films of lovastatin. The prepared formulations of films were evaluated for film thickness measurement, folding endurance study, in-vitro disintegration time, in-vitro drug release pattern and drug content. FTIR spectroscopy used to study drug-polymers interaction. Among all formulations, the formulation (F8) prepared by 4% crospovidone show enhanced drug release (99.27%) and it showed good stability for period of three months. Conclusively, the present study documents the development of a commercially viable formula lovastatin ODTs with rapidity in reducing heart problems.
Keywords:
Croscarmellose sodium; Crospovidone; Lovastatin; Oral disintegrating thin films
Full text article in PDF:
Copyright information:
Copyright © 2018 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.
